EMEA's Committee for Human Medicinal Products reviews heparin issues

The EMEA's Committee for Human Medicinal Products (CHMP) is reviewing issues related to the treatment with and supply of heparin products. The review was initiated following the detection of a contaminant in batches of medicinal products containing or derived from heparin in the USA and a few EU countries.

The procedure was initiated at the request of Germany under Article 5(3) of Regulation (EC) No 726/2004.

You can read our previous heparin announcements in the factbox to the right.

For further information, please contact Chief Medical Officer Steffen Thirstrup, tel. +45 4488 9187.

Danish Medicines Agency, 25 April 2008